How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Different share classes affect investment benefits, such as voting rights and dividend priorities. Mutual funds share classes vary by when and how load fees are charged and can affect long-term costs.

If you love to mix up your workouts with Pilates, spin, boxing, HIIT, yoga, reformer classes, and more, ClassPass is worth considering. The class-booking platform lets you try thousands of workouts ...

As an editor and writer who has contributed to many national and local publications, Nicole Gregory enjoys communicating clearly on critical health topics so that readers can make informed choices for ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Michael Boyle is an experienced financial professional with more ...